A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects With Treatment-resistant Depression

Trial Profile

A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects With Treatment-resistant Depression

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Esketamine (Primary) ; Duloxetine; Escitalopram; Sertraline; Venlafaxine
  • Indications Depression; Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms TRANSFORM-3
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 26 Sep 2017 Status changed from recruiting to completed.
    • 30 Jun 2017 Planned End Date changed from 26 Jun 2018 to 26 Mar 2021.
    • 08 May 2017 Planned End Date changed from 18 May 2021 to 26 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top